U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H34O5
Molecular Weight 390.5139
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TREPROSTINIL

SMILES

CCCCC[C@@]([H])(CC[C@]1([H])[C@@]2([H])Cc3cccc(c3C[C@@]2([H])C[C@@]1([H])O)OCC(=O)O)O

InChI

InChIKey=PAJMKGZZBBTTOY-ZFORQUDYSA-N
InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H34O5
Molecular Weight 390.5139
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412595/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515411/

Treprostinil (marketed under the trade names Remodulin for infusion) is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) is a disease in which blood pressure is abnormally high in the arteries between the heart and lungs. PAH is characterized by symptoms of shortness of breath during physical exertion. The condition can ultimately lead to heart failure. Treprostinil is a potent oral antiplatelet agent. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. Other studies have shown that treprostinil causes a dose-related negative inotropic and lusitropic effect. No major effects on cardiac conduction have been observed. Treprostinil had high affinity for the Prostaglandin D2 receptor (DP1), Prostaglandin E2 receptor EP2 subtype (EP2) and Prostaglandin D2 receptor (IP) receptors (Ki 4.4, 3.6 and 32 nM, respectively), low affinity for EP1 and EP4 receptors and even lower affinity for EP3, Prostaglandin F (FP) and thromboxane (TP) receptors. Treprostinil has demonstrated a unique effect on PPAR gamma, a transcription factor important in vascular pathogenesis as a mediator of proliferation, inflammation and apoptosis. Through a complementary, yet cyclic AMP-independent pathway, treprostinil activates PPARs, another mechanism that contributes to the anti-growth benefits of the prostacyclin class.

Originator

Curator's Comment:: By 1976, Vane and fellow researcher Salvador Moncada published the first paper on prostacyclin, in the scientific journal Nature. The collaboration produced a synthetic molecule which was given the name epoprostenol. But like native prostacyclin, the structure of the epoprostenol molecule proved to be unstable in solution, prone to rapid degradation. This presented a challenge for both in vitro experiments and clinical applications. To overcome this challenge, the research team that discovered prostacyclin was determined to continue the research in an attempt to build upon the success they had seen with the prototype molecule. The research team synthesized nearly 1,000 analogs.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
REMODULIN

Approved Use

Remodulin is a prostacyclin vasodilator indicated for: Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%) (1.1) Patients who require transition from Flolan®, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. (1.2) 1.1 Pulmonary Arterial Hypertension Remodulin is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%) [see Clinical Studies (14.1)

Launch Date

1.02193922E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.71 ng/mL
0.5 mg 3 times / day multiple, oral
dose: 0.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TREPROSTINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
0.54 ng/mL
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TREPROSTINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6.53 ng × h/mL
0.5 mg 3 times / day multiple, oral
dose: 0.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TREPROSTINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.46 ng × h/mL
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TREPROSTINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.34 h
0.5 mg 3 times / day multiple, oral
dose: 0.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TREPROSTINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
1.06 h
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TREPROSTINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
9%
TREPROSTINIL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg 3 times / day steady, subcutaneous
Overdose
Dose: 20 mg, 3 times / day
Route: subcutaneous
Route: steady
Dose: 20 mg, 3 times / day
Co-administed with::
chlorothiazide(500 mg)
lasix(40 mg)
coumadin(4 mg)
Sources:
unhealthy, 10 years
n = 1
Health Status: unhealthy
Condition: pulmonary hypertension
Age Group: 10 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Nausea, Blurred vision...
AEs leading to
discontinuation/dose reduction:
Nausea (1 patient)
Blurred vision (1 patient)
Sources:
7.5 mg single, subcutaneous
Overdose
Dose: 7.5 mg
Route: subcutaneous
Route: single
Dose: 7.5 mg
Sources:
unhealthy, 29 years
n = 1
Health Status: unhealthy
Condition: group 1 pulmonary arterial hypertension
Age Group: 29 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Circulatory collapse...
AEs leading to
discontinuation/dose reduction:
Circulatory collapse (1 patient)
Sources:
150 ug single, respiratory
Highest studied dose
Dose: 150 ug
Route: respiratory
Route: single
Dose: 150 ug
Sources:
healthy, 30.3 years
n = 43
Health Status: healthy
Age Group: 30.3 years
Sex: M+F
Population Size: 43
Sources:
Other AEs: Cough, Throat irritation...
Other AEs:
Cough (26 patients)
Throat irritation (26 patients)
Sources:
100 mg single, subcutaneous (min)
Overdose
Dose: 100 mg
Route: subcutaneous
Route: single
Dose: 100 mg
Sources:
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: CREST syndrome, Raynaud's syndrome, esophageal motility impairment, and severe pulmonary hypertension
Age Group: 58 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Hypotension, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Hypotension (1 patient)
Tachycardia (1 patient)
Arrhythmia ventricular (1 patient)
Dyspnea (1 patient)
Sources:
36 ug 4 times / day steady, respiratory (max)
Recommended
Dose: 36 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 36 ug, 4 times / day
Sources:
unhealthy, 7.1 - 19.2 years
n = 29
Health Status: unhealthy
Condition: pulmonary hypertension
Age Group: 7.1 - 19.2 years
Sex: M+F
Population Size: 29
Sources:
Disc. AE: Bronchospasm...
AEs leading to
discontinuation/dose reduction:
Bronchospasm (3 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Blurred vision 1 patient
Disc. AE
20 mg 3 times / day steady, subcutaneous
Overdose
Dose: 20 mg, 3 times / day
Route: subcutaneous
Route: steady
Dose: 20 mg, 3 times / day
Co-administed with::
chlorothiazide(500 mg)
lasix(40 mg)
coumadin(4 mg)
Sources:
unhealthy, 10 years
n = 1
Health Status: unhealthy
Condition: pulmonary hypertension
Age Group: 10 years
Sex: F
Population Size: 1
Sources:
Nausea 1 patient
Disc. AE
20 mg 3 times / day steady, subcutaneous
Overdose
Dose: 20 mg, 3 times / day
Route: subcutaneous
Route: steady
Dose: 20 mg, 3 times / day
Co-administed with::
chlorothiazide(500 mg)
lasix(40 mg)
coumadin(4 mg)
Sources:
unhealthy, 10 years
n = 1
Health Status: unhealthy
Condition: pulmonary hypertension
Age Group: 10 years
Sex: F
Population Size: 1
Sources:
Circulatory collapse 1 patient
Disc. AE
7.5 mg single, subcutaneous
Overdose
Dose: 7.5 mg
Route: subcutaneous
Route: single
Dose: 7.5 mg
Sources:
unhealthy, 29 years
n = 1
Health Status: unhealthy
Condition: group 1 pulmonary arterial hypertension
Age Group: 29 years
Sex: F
Population Size: 1
Sources:
Cough 26 patients
150 ug single, respiratory
Highest studied dose
Dose: 150 ug
Route: respiratory
Route: single
Dose: 150 ug
Sources:
healthy, 30.3 years
n = 43
Health Status: healthy
Age Group: 30.3 years
Sex: M+F
Population Size: 43
Sources:
Throat irritation 26 patients
150 ug single, respiratory
Highest studied dose
Dose: 150 ug
Route: respiratory
Route: single
Dose: 150 ug
Sources:
healthy, 30.3 years
n = 43
Health Status: healthy
Age Group: 30.3 years
Sex: M+F
Population Size: 43
Sources:
Arrhythmia ventricular 1 patient
Disc. AE
100 mg single, subcutaneous (min)
Overdose
Dose: 100 mg
Route: subcutaneous
Route: single
Dose: 100 mg
Sources:
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: CREST syndrome, Raynaud's syndrome, esophageal motility impairment, and severe pulmonary hypertension
Age Group: 58 years
Sex: F
Population Size: 1
Sources:
Dyspnea 1 patient
Disc. AE
100 mg single, subcutaneous (min)
Overdose
Dose: 100 mg
Route: subcutaneous
Route: single
Dose: 100 mg
Sources:
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: CREST syndrome, Raynaud's syndrome, esophageal motility impairment, and severe pulmonary hypertension
Age Group: 58 years
Sex: F
Population Size: 1
Sources:
Hypotension 1 patient
Disc. AE
100 mg single, subcutaneous (min)
Overdose
Dose: 100 mg
Route: subcutaneous
Route: single
Dose: 100 mg
Sources:
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: CREST syndrome, Raynaud's syndrome, esophageal motility impairment, and severe pulmonary hypertension
Age Group: 58 years
Sex: F
Population Size: 1
Sources:
Tachycardia 1 patient
Disc. AE
100 mg single, subcutaneous (min)
Overdose
Dose: 100 mg
Route: subcutaneous
Route: single
Dose: 100 mg
Sources:
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: CREST syndrome, Raynaud's syndrome, esophageal motility impairment, and severe pulmonary hypertension
Age Group: 58 years
Sex: F
Population Size: 1
Sources:
Bronchospasm 3 patients
Disc. AE
36 ug 4 times / day steady, respiratory (max)
Recommended
Dose: 36 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 36 ug, 4 times / day
Sources:
unhealthy, 7.1 - 19.2 years
n = 29
Health Status: unhealthy
Condition: pulmonary hypertension
Age Group: 7.1 - 19.2 years
Sex: M+F
Population Size: 29
Sources:
Overview

OverviewOther

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: Treprostinil plasma AUC and Cmax increased approximately 2-fold when administered with gemfibrozil; Treprostinil AUC decreased by 30% when adminsitered with rifampin;
Page: 12,14
minor
weak (co-administration study)
Comment: Treprostinil AUC decreased approximately 14%, no effect on Cmax when adminstered with fluconazole;
Page: 12,14
no
no
no
no
no
no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Gateways to clinical trials.
2002 Dec
Gateways to clinical trials.
2003 Sep
Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers.
2004 Aug
Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.
2004 Jan
Gateways to clinical trials.
2004 Jul-Aug
Gateways to clinical trials.
2004 Jun
Treprostinil for pulmonary hypertension.
2004 Mar
Gateways to clinical trials.
2004 Mar
Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension.
2005 Apr
Gateways to clinical trials.
2005 Jan-Feb
Gateways to clinical trials.
2005 Jun
Gateways to clinical trials.
2005 Sep
Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts.
2006 Feb
[The best of clinical cardiovascular pharmacology in 2005].
2006 Jan
Gateways to clinical trials.
2006 Jan-Feb
The prostacyclin analog, treprostinil sodium, provides symptom relief in severe Buerger's disease--a case report and review of literature.
2006 Jan-Feb
Treprostinil sodium (Remodulin), a prostacyclin analog, in the treatment of critical limb ischemia: open-label study.
2006 May-Jun
Gateways to clinical trials.
2006 Sep
The role of peroxisome proliferator-activated receptors in pulmonary vascular disease.
2007
Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
2007 Mar 2
Gateways to clinical trials.
2007 Nov
Treprostinil for pulmonary hypertension.
2008
Patient safety challenges in treprostinil therapy.
2008 Apr
A novel catheter system for totally implantable intravenous drug therapy: assessment of catheter function and patency with trepostinil therapy.
2008 Jan-Mar
Primary pulmonary hypertension as a manifestation of adult multi-system mitochondrial disorder.
2009 Apr 30
Gateways to clinical trials.
2009 Sep
Inhaled treprostinil and pulmonary arterial hypertension.
2010 Dec 3
Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.
2010 Jan 29
The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension.
2010 Mar 4
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Treprostinil is available in three different formulations and four different routes of administration: Remodulin® (treprostinil sodium, intravenous and subcutaneous administration), Tyvaso® (treprostinil sodium, inhaled administration), and Orenitram® (treprostinil diolamine, oral administration) for the treatment of pulmonary arterial hypertension (PAH). https://www.ncbi.nlm.nih.gov/pubmed/?term=27286723
1.25 ng/kg/min (initial dose for continuous infusion, dosage should be chronically adjusted depending on clinical response)
Route of Administration: Other
In Vitro Use Guide
Curator's Comment:: Treprostinil (0.15 - 15 ng/ml) slightly increased contractile dynamics of cardiomyocytes at clinically relevant concentrations.
Treprostinil (0.15 - 15 ng/ml) rat cardiomyocytes
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:32:04 UTC 2021
Edited
by admin
on Fri Jun 25 21:32:04 UTC 2021
Record UNII
RUM6K67ESG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TREPROSTINIL
INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
RUMODOLIN
Brand Name English
LRX-15
Code English
TREPROSTINIL [USAN]
Common Name English
L606
Code English
TREPROSTINIL [INN]
Common Name English
L-606
Code English
((1R,2R,3AS,9AS)-2-HYDROXY-1-((3S)-3-HYDROXYOCTYL)-2,3,3A,4,9,9A-HEXAHYDRO-1H-CYLOPENT(B)NAPHTHALEN-5-YL)OXY)ACETATE
Common Name English
TYVASO
Brand Name English
REMODULIN
Brand Name English
15-AU-81
Code English
TREPROSTINIL [ORANGE BOOK]
Common Name English
TREPROSTINIL [MART.]
Common Name English
TREPROSTINIL [WHO-DD]
Common Name English
UT-15
Code English
TREPROSTINIL [VANDF]
Common Name English
UNIPROST
Brand Name English
15AU81
Code English
TREPROSTINIL [MI]
Common Name English
ACETIC ACID,(((1R,2R,3AS,9AS)-2,3,3A,4,9,9A-HEXAHYDRO-2-HYDROXY-1-((3S)-3-HYDROXYOCTYL)-1H-BENZ(F)INDEN-5-YL)OXY)-
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 189104
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
WHO-ATC B01AC21
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
NDF-RT N0000011280
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
NCI_THESAURUS C78568
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
LIVERTOX 992
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
NCI_THESAURUS C29707
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
FDA ORPHAN DRUG 105197
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
FDA ORPHAN DRUG 711319
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
NDF-RT N0000009909
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
NDF-RT N0000011280
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
WHO-VATC QB01AC21
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
NDF-RT N0000011280
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
FDA ORPHAN DRUG 787620
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
NDF-RT N0000175416
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
Code System Code Type Description
LACTMED
Treprostinil
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
PRIMARY
INN
8170
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
PRIMARY
MERCK INDEX
M11018
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
PRIMARY Merck Index
IUPHAR
5820
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
PRIMARY
DRUG CENTRAL
2720
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
PRIMARY
RXCUI
343048
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
PRIMARY RxNorm
FDA UNII
RUM6K67ESG
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
PRIMARY
EVMPD
SUB21168
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
PRIMARY
PUBCHEM
6918140
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
PRIMARY
CAS
81846-19-7
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
PRIMARY
NCI_THESAURUS
C61983
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
PRIMARY
WIKIPEDIA
TREPROSTINIL
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
PRIMARY
DRUG BANK
DB00374
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
PRIMARY
ChEMBL
CHEMBL1237119
Created by admin on Fri Jun 25 21:32:04 UTC 2021 , Edited by admin on Fri Jun 25 21:32:04 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
BINDER->LIGAND
BINDING
TARGET -> AGONIST
TARGET -> AGONIST
EXCRETED UNCHANGED
URINE
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC